Fmoc-N-（1-Boc-哌啶-4-基）甘氨酸 | 269078-80-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 中文名称: Fmoc-N-（1-Boc-哌啶-4-基）甘氨酸
• 中文别名: FMOC-N-(1-BOC-4-哌啶基)甘氨酸
• 英文名称: Fmoc-N-(1-Boc-4-piperidyl)glycine
• 英文别名: 2-[9H-fluoren-9-ylmethoxycarbonyl-[1-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-4-yl]amino]acetic acid
• CAS: 269078-80-0
• 化学式: C₂₇H₃₂N₂O₆
• 分子量: 480.561
• InChiKey: VDSAYWOINWZBBH-UHFFFAOYSA-N

物化性质

• 沸点：
  645.4±55.0 °C(Predicted)
• 密度：
  1.29±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  35
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  96.4
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  Fmoc-N-（1-Boc-哌啶-4-基）甘氨酸 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 以100%的产率得到Fmoc-N-(4-piperidyl)glycine
  参考文献：
  名称：

  Synthesis of a novel Fmoc-protected nucleoaminoacid for the solid phase assembly of 4-piperidyl glycine/l-arginine-containing nucleopeptides and preliminary RNA interaction studies

  摘要：

  In this work, we report the synthesis of a novel Fmoc-protected nucleoaminoacid, based on 4-piperidinyl glycine, carrying the DNA nucleobase on the secondary amino group, suitable for the solid-phase synthesis of nucleopeptides. After ESI-MS and NMR characterization this building block was used for the assembly of a thymine-functionalized tetrapeptide, composed of 4-piperidinyl glycine and l-arginine moieties alternated in the backbone. The ability to interact with RNA and the efficiency in interfering with the reverse transcription of eukaryotic mRNA of the novel nucleo-tetrapeptide found in this study are in favour of the employment of chiral nucleopeptides based on alternate 4-piperidinyl glycine/l-arginine backbone in biomedicine.

  DOI：

  10.1007/s00726-010-0532-4

文献信息

• Compounds That Inhibit Replication Of Human Immunodeficiency Virus
  申请人：Balzarini Maria Rene Jan

  公开号：US20080076824A1

  公开（公告）日：2008-03-27

  The present invention relates to the discovery of a novel class of compounds that inhibit the replication of human immunodeficiency virus (HIV) and approaches to identify these compounds. More specifically, it has been found that enzymatically prepared alpha-hydroxyglycinamide and synthetically prepared alpha-hydroxyglycinamide inhibit the replication of HIV in human serum. Embodiments include methods to identify modified glycinamide compounds that inhibit HUV, methods to isolate and synthesize modified glycinamide compounds, and therapeutic compositions comprising these compounds.

  本发明涉及一种新型化合物类别的发现，该类化合物能够抑制人类免疫缺陷病毒（HIV）的复制，并提供了鉴定这些化合物的方法。具体来说，发现经酶法制备的α-羟基甘氨酰胺和人工合成的α-羟基甘氨酰胺能够抑制HIV在人血清中的复制。实施例包括鉴定抑制HUV的改性甘氨酰胺化合物的方法，分离和合成改性甘氨酰胺化合物的方法，以及包含这些化合物的治疗组合物。
• Peptidomimetics selective for the somatostatin receptor subtypes 1 and/or 4
  申请人：Tomperi Jussi

  公开号：US20100048549A1

  公开（公告）日：2010-02-25

  The invention relates to (hetero)arylsulfonylamino based peptidomimetics of formula (I), wherein A, D, E, J, Q1 R1, R2, R3, p and j are defined as disclosed, or a pharmaceutically acceptable salt or ester thereof. Compounds of formula (I) possess high affinity and selectivity for the somatostatin receptor subtypes sst 1 and/or sst 4 and can be used for the treatment or diagnosis of diseases or conditions wherein sst 1 and/or sst 4 agonists or antagonists are indicated to be useful.

  本发明涉及公式（I）中基于（杂）芳基磺酰氨基的肽类类似物，其中A，D，E，J，Q1，R1，R2，R3，p和j如所述定义，或其药学上可接受的盐或酯。公式（I）化合物具有对生长抑素受体亚型sst1和/或sst4的高亲和力和选择性，并可用于治疗或诊断sst1和/或sst4激动剂或拮抗剂被认为有用的疾病或情况。
• Stabilized minimal coiled-coil mimetics
  申请人：NEW YORK UNIVERSITY

  公开号：US10851133B2

  公开（公告）日：2020-12-01

  This invention relates to a macrostructure that includes an antiparallel coiled-coil structure shown below or a parallel coiled-coil structure shown below and described in the present application.

  本发明涉及一种宏观结构，它包括下图所示的反平行盘卷结构或下图所示的平行盘卷结构，并在本申请中进行了描述。
• LOW AFFINITY SCREENING METHOD
  申请人：Graffinity Pharmaceuticals Aktiengesellschaft

  公开号：EP1360489A1

  公开（公告）日：2003-11-12
• STABILIZED MINIMAL COILED-COIL MIMETICS
  申请人：New York University

  公开号：EP3303367A1

  公开（公告）日：2018-04-11